Intrinsic regulation of hemangioma involution by platelet-derived growth factor

Cell Death and Disease

Volumn 3, Issue 6, 2012, Pages

  Roach, E E ^a   Chakrabarti, R ^a   Park, N I ^a   Keats, E C ^a   Yip, J ^a   Chan, N G ^a,b   Khan, Z A ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

adipogenesis; cell fate; differentiation; endothelial cells; hemangioma; stem cells

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TYROSINE; CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; HEMANGIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL; VASCULAR TUMOR; CANCER STEM CELL; CELL PROLIFERATION; ENDOTHELIUM CELL; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

MUS;

ADIPOCYTES; ANTIGENS, CD; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOTHELIAL CELLS; GLYCOPROTEINS; HEMANGIOMA; HUMANS; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASTIC STEM CELLS; PEPTIDES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84863442439     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.58     Document Type: Article

References (36)

1. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000; 37: 517-584.
2. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA et al. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882-887.
3. Boscolo E, Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis 2009; 12: 197-207.
4. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC et al. Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics 2008; 122: 360-367.
5. Walter JW, Blei F, Anderson JL, Orlow SJ, Speer MC, Marchuk DA. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 1999; 82: 77-83.
6. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 2002; 99: 7455-7460.
7. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-1257.
8. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316.
9. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245.
10. Beck L Jr., D'Amore PA. Vascular development: Cellular and molecular regulation. FASEB J 1997; 11: 365-373.
11. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine growth factor rev 2004; 15: 205-213.
12. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994; 93: 1266-1274.
13. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990; 85: 916-920.
14. Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118: 2592-2599.
15. Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL et al. Human adipocyte lipid-binding protein: Purification of the protein and cloning of its complementary DNA. Biochemistry 1989; 28: 8683-8690.
16. Cristancho AG, Lazar MA. Forming functional fat: A growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 12: 722-734.
17. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998; 78: 783-809.
18. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010; 362: 1005-1013.
19. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14: 1236-1246.
20. Boscolo E, Mulliken JB, Bischoff J. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2011; 179: 2266-2277.
21. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell 2011; 2: 845-854.
22. Bryckaert MC, Eldor A, Fontenay M, Gazit A, Osherov N, Gilon C et al. Inhibition of plateletderived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. Exp Cell Res 1992; 199: 255-261.
23. D'Andrea MR, Mei JM, Tuman RW, Galemmo RA, Johnson DL. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther 2005; 4: 1198-1204.
24. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-Transformation. Cancer Res 1994; 54: 6106-6114.
25. Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P et al. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther 1998; 285: 844-852.
26. Faraone D, Aguzzi MS, Ragone G, Russo K, Capogrossi MC, Facchiano A. Heterodimerization of FGF-receptor 1 and PDGF-receptor-Alpha: A novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 n human cells. Blood 2006; 107: 1896-1902.
27. Bachmeier M, Loffler G. Influence of growth factors on growth and differentiation of 3T3-L1 preadipocytes in serum-free conditions. Eur J Cell Biol 1995; 68: 323-329.
28. Bachmeier M, Loffler G. The effect of platelet-derived growth factor and adipogenic hormones on the expression of CCAAT/enhancer-binding proteins in 3T3-L1 cells in serum-free conditions. Eur J Biochem 1997; 243: 128-133.
29. Vaziri C, Faller DV. Down-regulation of platelet-derived growth factor receptor expression during terminal differentiation of 3T3-L1 pre-Adipocyte fibroblasts. J Biol Chem 1996; 271: 13642-13648.
30. Cook JR, Kozak LP. Sn-glycerol-3-phosphate dehydrogenase gene expression during mouse adipocyte development in vivo. Dev Biol 1982; 92: 440-448.
31. Widberg CH, Newell FS, Bachmann AW, Ramnoruth SN, Spelta MC, Whitehead JP et al. Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes. Am J Physiol Endocrinol Metab 2009; 296: E121-E131.
32. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295.
33. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-Tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-952.
34. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J cell biol 1994; 125: 917-928.
35. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995; 267: 1782-1788.
36. Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer FD. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-Activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem 1996; 39: 2170-217